^
Association details:
| Biomarker: | IRF4 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | (bortezomib + dexamethasone injection + lenalidomide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Published date:
12/08/2020
Excerpt:
The multivariate Cox model identified high levels of PSMD10 (hazard ratio [HR] TTP, 3.49; P = .036; HR PFS, 5.33; P = .004) and Ikaros (HR TTP, 3.01, P = .014; HR PFS, 2.57; P = .028), and low levels of IRF4 protein expression (HR TTP, 0.33; P = .004; HR PFS, 0.35; P = .004) along with high-risk cytogenetics (HR TTP, 3.13; P < .001; HR PFS, 2.69; P = .002), as independently associated with shorter TTP and PFS.
DOI:
10.1182/bloodadvances.2020002711
